{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:31:14Z","timestamp":1788967874945,"version":"build-2803163510"},"reference-count":107,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:p>Pseudomyxoma peritonei is an infrequent solid tumor in clinical practice. The low morbidity and deficient understanding of this mucus-secreting malignant disease increase the risks of delayed identification or uncontrollable deterioration. In quite a lot cases, patients go through complete cytoreduction surgery and hyperthermic intraperitoneal chemotherapy could receive a long time survival over 5 years. But the recurrence rate is also hard to overlook. Unlike other types of cancer, the standard treatment for this considerable groups has not been confirmed yet. With the advanced medical progression, studies have been carrying out based on pathogenesis, biological characters, and mutated gene location. All but a few get statistical survival benefits, let alone the breaking progress on research or therapeutic practice in the field. We try to give a comprehensive exposition of pseudomyxoma peritonei around the epidemiology, radiologic features, clinical manifestation, present treatment and promising schemes, hoping to arise much attention and reflection on the feasible solutions, especially for the recrudescent part.<\/jats:p>","DOI":"10.1097\/coc.0000000000000911","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T14:00:38Z","timestamp":1650549638000},"page":"223-231","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Comprehensive Understanding and Evolutional Therapeutic Schemes for Pseudomyxoma Peritonei"],"prefix":"10.1097","volume":"45","author":[{"given":"Suiting","family":"Ye","sequence":"first","affiliation":[{"name":"Fourth School of Clinical Medicine, Zhejiang Chinese Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hangzhou First People\u2019s Hospital"},{"name":"Department of Oncology, Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine"},{"name":"Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4240\/wjgs.v10.i5.49","article-title":"Approach to pseudomyxoma peritonei","volume":"10","author":"Rizvi","year":"2018","journal-title":"World J Gastrointest Surg"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s12029-018-00192-8","article-title":"Pseudomyxoma peritonei: case report and literature review","volume":"50","author":"Garc\u00eda","year":"2019","journal-title":"J Gastrointest Cancer"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejso.2020.02.012","article-title":"Appendiceal tumours and pseudomyxoma peritonei: literature review with PSOGI\/EURACAN clinical practice guidelines for diagnosis and treatment","volume":"47","author":"Govaerts","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0002-9610(37)90763-3","article-title":"Mucocele of appendix with pseudomucinous degeneration","volume":"36","author":"Weaver","year":"1937","journal-title":"Am J Surg"},{"key":"R5-20250527","first-page":"100","article-title":"Klinische und Anatomische Untersuchungen zur Lehre von den Bauchgeschwullsten und der Laparotomie","volume":"24","author":"Werth","year":"1884","journal-title":"Arch Gynecol Obstet"},{"key":"R6-20250527","first-page":"965","article-title":"Uber das sogenannte pseudomyxoma peritonei","volume":"48","author":"Frankel","year":"1901","journal-title":"Med Wochenschr"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/00365521.2017.1284896","article-title":"Diagnosis of Pseudomyxoma peritonei via endoscopic ultrasound guided fine needle aspiration: a case report and review of literature","volume":"52","author":"Darr","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"355","DOI":"10.12659\/AJCR.890837","article-title":"Appendiceal mucocele and pseudomyxoma peritonei: the clinical boundaries of a subtle disease","volume":"15","author":"Spyropoulos","year":"2014","journal-title":"Am J case rep"},{"key":"R9-20250527","first-page":"759","article-title":"Pseudomyxoma peritonei\u2014a case report","volume":"21","author":"Laila","year":"2012","journal-title":"Mymensingh Med J"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.pan.2020.06.008","article-title":"Immunohistochemical staining as supportive diagnostic tool for pseudomyxoma peritonei arising from intraductal papillary mucinous neoplasm: a report of two cases and literature review","volume":"20","author":"Kataoka","year":"2020","journal-title":"Pancreatology"},{"key":"R11-20250527","first-page":"e4666","article-title":"Gelatinous abdomen: a rare case of pseudomyxoma peritonei arising from metastatic gastric adenocarcinoma","volume":"11","author":"Wang","year":"2019","journal-title":"Cureus"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1746-1596-7-10","article-title":"Carcinoma involving the gallbladder: a retrospective review of 23 cases\u2014pitfalls in diagnosis of gallbladder carcinoma","volume":"7","author":"Giang","year":"2012","journal-title":"Diagn Pathol"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/modpathol.3880370","article-title":"Gelatinous ascites: a cytohistologic study of pseudomyxoma peritonei in 67 patients","volume":"14","author":"Jackson","year":"2001","journal-title":"Mod Pathol"},{"key":"R14-20250527","first-page":"363","article-title":"Muzin\u00f6se Metaplasie der Tubenschleimhaut als Ursache eines Pseudomyxoma peritonei [German] [Mucinous metaplasia of fallopian tube mucous membrane as a cause of pseudomyxoma peritonei]","volume":"138","author":"Minguillon","year":"1992","journal-title":"Zentralbl Pathol"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/BF02358375","article-title":"Pseudomyxoma peritonei due to adenocarcinoma of the lung: case report","volume":"29","author":"Kurita","year":"1994","journal-title":"J Gastroenterol"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/BF01887311","article-title":"Pseudomyxoma peritonei from metastatic colloid carcinoma of the breast","volume":"16","author":"Hawes","year":"1991","journal-title":"Gastrointest Radiol"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.3747\/co.21.1695","article-title":"Pseudomyxoma peritonei originating from urachus-case report and review of the literature","volume":"21","author":"Agrawal","year":"2014","journal-title":"Curr Oncol"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1471-0528.1921.tb07782.x","article-title":"On the pseudomyxoma peritonei","volume":"28","author":"Krivsky","year":"1921","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/00000478-199512000-00006","article-title":"Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to \u201cpseudomyxoma peritonei\u201d","volume":"19","author":"Ronnett","year":"1995","journal-title":"Am J Surg Pathol"},{"issue":"suppl 1","key":"R20-20250527","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1038\/modpathol.2014.129","article-title":"Mucinous epithelial neoplasms of the appendix and pseudomyxoma peritonei","volume":"28","author":"Misdraji","year":"2015","journal-title":"Mod Pathol"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.5858\/arpa.2011-0034-RA","article-title":"Mucinous neoplasms of the appendix and peritoneum","volume":"135","author":"Panarelli","year":"2011","journal-title":"Arch Path Lab Med"},{"key":"R23-20250527","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/PAS.0000000000000535","article-title":"A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process","volume":"40","author":"Carr","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R24-20250527","article-title":"Which classification system defines best prognosis of mucinous neoplasms of the appendix with peritoneal dissemination: TNM vs PSOGI?","author":"Mart\u00edn-Rom\u00e1n","year":"2021","journal-title":"J Clin Pathol"},{"key":"R25-20250527","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ctrv.2006.11.001","article-title":"Pseudomyxoma peritonei","volume":"33","author":"Smeenk","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"R26-20250527","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/BF02053933","article-title":"Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy","volume":"36","author":"Sugarbaker","year":"1993","journal-title":"Dis Colon Rectum"},{"key":"R27-20250527","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S1055-3207(03)00048-6","article-title":"Peritonectomy procedures","volume":"12","author":"Sugarbaker","year":"2003","journal-title":"Surg Oncol Clin N Am"},{"key":"R28-20250527","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF00308632","article-title":"Patient selection and treatment of peritoneal carcinomatosis from colorectal and appendiceal cancer","volume":"19","author":"Sugarbaker","year":"1995","journal-title":"World J Surg"},{"key":"R29-20250527","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J Clin Oncol"},{"key":"R30-20250527","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat Res"},{"key":"R31-20250527","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","article-title":"Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study","volume":"22","author":"Glehen","year":"2004","journal-title":"J Clin Oncol"},{"key":"R32-20250527","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/02656736.2017.1310938","article-title":"Pseudomyxoma peritonei: natural history and treatment","volume":"33","author":"Mittal","year":"2017","journal-title":"Int J Hyperthermia"},{"key":"R33-20250527","first-page":"233","article-title":"Pseudomyxoma peritonei syndrome","volume":"30","author":"Sugarbaker","year":"1996","journal-title":"Adv Surg"},{"key":"R34-20250527","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1590\/0100-3984.2019.0044","article-title":"The many faces of pseudomyxoma peritonei: a radiological review based on 30 cases","volume":"52","author":"Fonseca","year":"2019","journal-title":"Radiol Bras"},{"key":"R35-20250527","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2214\/ajr.119.1.198","article-title":"Distribution of intra-abdominal malignant seeding: dependency on dynamics of flow of ascitic fluid","volume":"119","author":"Meyers","year":"1973","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"R36-20250527","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/his.13324","article-title":"The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei","volume":"71","author":"Carr","year":"2017","journal-title":"Histopathology"},{"key":"R37-20250527","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ejso.2016.01.005","article-title":"Preoperative CT and MRI prediction of non-resectability in patients treated for pseudomyxoma peritonei from mucinous appendiceal neoplasms","volume":"42","author":"Menassel","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"R38-20250527","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1245\/s10434-020-08234-x","article-title":"The pathologic peritoneal cancer index (PCI) strongly differs from the surgical PCI in peritoneal metastases arising from various primary tumors","volume":"27","author":"Bhatt","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"R39-20250527","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejso.2017.11.003","article-title":"Prognostic value of peritoneal cancer index in primary advanced ovarian cancer","volume":"44","author":"Llueca","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"R40-20250527","first-page":"373","article-title":"Peritonectomy HIPEC-contemporary results, indications","volume":"25","author":"Morris","year":"2013","journal-title":"Chin J Cancer Res"},{"key":"R41-20250527","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s13304-020-00842-2","article-title":"Clinical findings of patients with pseudomyxoma peritonei of appendiceal origin undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"72","author":"Iavazzo","year":"2020","journal-title":"Updates Surg"},{"key":"R42-20250527","doi-asserted-by":"crossref","first-page":"554910","DOI":"10.3389\/fsurg.2020.554910","article-title":"The prognostic impact of pathology on patients with pseudomyxoma peritonei undergoing debulking surgery: a systematic review and meta-analysis of retrospective studies","volume":"7","author":"Zhou","year":"2020","journal-title":"Front Surg"},{"key":"R43-20250527","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1245\/s10434-015-5019-9","article-title":"Can a benefit be expected from surgical debulking of unresectable pseudomyxoma peritonei?","volume":"23","author":"Delhorme","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"R44-20250527","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/01.sla.0000152015.76731.1f","article-title":"Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy","volume":"241","author":"Miner","year":"2005","journal-title":"Ann Surg"},{"key":"R45-20250527","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12957-021-02171-z","article-title":"Two-step cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei with high peritoneal carcinomatosis index","volume":"19","author":"Trilling","year":"2021","journal-title":"World J Surg Oncol"},{"key":"R46-20250527","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s11605-019-04239-4","article-title":"Outcomes following cytoreduction and HIPEC for pseudomyxoma peritonei: 10-year experience","volume":"24","author":"Narasimhan","year":"2020","journal-title":"J Gastrointest Surg"},{"key":"R47-20250527","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ygyno.2020.07.017","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC): should we look closer at the microenvironment?","volume":"159","author":"Crestani","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R48-20250527","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4251\/wjgo.v2.i2.68","article-title":"Hyperthermic intraperitoneal chemotherapy: rationale and technique","volume":"2","author":"Gonz\u00e1lez-Moreno","year":"2010","journal-title":"World J Gastrointest Oncol"},{"key":"R50-20250527","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13023-021-01723-6","article-title":"Consensuses and controversies on pseudomyxoma peritonei: a review of the published consensus statements and guidelines","volume":"16","author":"Lin","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"R51-20250527","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/bjs.10716","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin","volume":"105","author":"Delhorme","year":"2018","journal-title":"Br J Surg"},{"key":"R52-20250527","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1007\/s00261-018-01888-y","article-title":"Mucinous appendiceal neoplasms: classification, imaging, and HIPEC","volume":"44","author":"Bartlett","year":"2019","journal-title":"Abdom Radiol (NY)"},{"key":"R53-20250527","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/bjs5.97","article-title":"Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"3","author":"Mercier","year":"2018","journal-title":"BJS Open"},{"key":"R54-20250527","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00261-017-1092-9","article-title":"Liver scalloping in pseudomyxoma peritonei","volume":"42","author":"Fonseca","year":"2017","journal-title":"Abdom Radiol (NY)"},{"key":"R55-20250527","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1007\/s00330-020-06756-2","article-title":"Pseudomyxoma peritonei: visceral scalloping on CT is a predictor of recurrence after complete cytoreductive surgery","volume":"30","author":"Hotta","year":"2020","journal-title":"Eur Radiol"},{"key":"R56-20250527","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1102\/1470-7330.2013.0044","article-title":"Correlation of preoperative magnetic resonance imaging of peritoneal carcinomatosis and clinical outcome after peritonectomy and HIPEC after 3 years of follow-up: preliminary results","volume":"13","author":"Klumpp","year":"2013","journal-title":"Cancer Imaging"},{"key":"R57-20250527","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.ejso.2018.06.023","article-title":"Single centre guidelines for radiological follow-up based on 775 patients treated by cytoreductive surgery and HIPEC for appendiceal pseudomyxoma peritonei","volume":"44","author":"Govaerts","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"R58-20250527","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1245\/s10434-017-6275-7","article-title":"Prediction of resectability in pseudomyxoma peritonei with a new CT score","volume":"25","author":"Bouquot","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R59-20250527","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1245\/s10434-014-4041-7","article-title":"Comparison of MRI and CT for predicting the Peritoneal Cancer Index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures","volume":"22","author":"Low","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R60-20250527","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.3390\/cancers13235965","article-title":"Novel perspectives in pseudomyxoma peritonei treatment","volume":"13","author":"Sommariva","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R61-20250527","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/01.pas.0000202039.74837.7d","article-title":"Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review","volume":"30","author":"Bradley","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"R62-20250527","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/sj.bjc.6604522","article-title":"A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei","volume":"99","author":"Farquharson","year":"2008","journal-title":"Br J Cancer"},{"key":"R63-20250527","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/j.clcc.2019.03.002","article-title":"Metronomic capecitabine with cyclophosphamide regimen in unresectable or relapsed pseudomyxoma peritonei","volume":"18","author":"Raimondi","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"R64-20250527","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1634\/theoncologist.2014-0106","article-title":"FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma","volume":"19","author":"Pietrantonio","year":"2014","journal-title":"Oncologist"},{"key":"R65-20250527","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s10147-019-01592-x","article-title":"Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei","volume":"25","author":"Hiraide","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"R66-20250527","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.gore.2014.10.001","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in a woman with pseudomyxoma peritonei: a case report","volume":"10","author":"Tempfer","year":"2014","journal-title":"Gynecol Oncol Rep"},{"key":"R67-20250527","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/02656736.2019.1704891","article-title":"PIPAC versus HIPEC: cisplatin spatial distribution and diffusion in a swine model","volume":"37","author":"Davigo","year":"2020","journal-title":"Int J Hyperthermia"},{"key":"R68-20250527","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","article-title":"Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications","volume":"20","author":"Alyami","year":"2019","journal-title":"Lancet Oncol"},{"key":"R69-20250527","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejso.2019.06.028","article-title":"Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"47","author":"Alyami","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"suppl 1","key":"R70-20250527","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.21037\/jgo-20-257","article-title":"Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with colorectal peritoneal metastases-a systematic review","volume":"12","author":"Lurvink","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"R71-20250527","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1245\/s10434-021-10899-x","article-title":"Is PIPAC a new summit for peritoneal disease treatment or are we lost in the snowstorm?","volume":"29","author":"Badgwell","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"R72-20250527","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygyno.2018.05.001","article-title":"A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis","volume":"150","author":"Tempfer","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R73-20250527","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.4161\/cbt.8.15.8943","article-title":"Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine","volume":"8","author":"Sun","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"R74-20250527","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.3390\/cancers13112819","article-title":"Anti-angiogenic treatment in pseudomyxoma peritonei-still a strong preclinical rationale","volume":"13","author":"Andersson","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R75-20250527","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.12998\/wjcc.v7.i22.3881","article-title":"Apatinib for treatment of a pseudomyxoma peritonei patient after surgical treatment and hyperthermic intraperitoneal chemotherapy: a case report","volume":"7","author":"Huang","year":"2019","journal-title":"World J Clin Cases"},{"key":"R76-20250527","doi-asserted-by":"crossref","first-page":"29","DOI":"10.21037\/cco-21-2","article-title":"A case of pseudomyxoma peritonei successfully treated with trifluridine\/tipiracil (TAS-102) and bevacizumab after palliative debulking surgery","volume":"10","author":"Hirano","year":"2021","journal-title":"Chin Clin Oncol"},{"key":"R77-20250527","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/biom10020255","article-title":"Revisiting the roles of pro-metastatic EpCAM in cancer","volume":"10","author":"Mohtar","year":"2020","journal-title":"Biomolecules"},{"key":"R78-20250527","doi-asserted-by":"crossref","first-page":"61800","DOI":"10.18632\/oncotarget.18694","article-title":"MOC31PE immunotoxin\u2014targeting peritoneal metastasis from epithelial ovarian cancer","volume":"8","author":"Andersson","year":"2017","journal-title":"Oncotarget"},{"key":"R79-20250527","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/ijc.28158","article-title":"Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies","volume":"133","author":"Flatmark","year":"2013","journal-title":"Int J Cancer"},{"key":"R80-20250527","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1245\/s10434-017-5814-6","article-title":"Novel treatment with intraperitoneal MOC31PE immunotoxin in colorectal peritoneal metastasis: results from the ImmunoPeCa Phase 1 Trial","volume":"24","author":"Fr\u00f8ysnes","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"R81-20250527","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejso.2019.04.014","article-title":"ImmunoPeCa trial: long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis","volume":"47","author":"Fr\u00f8ysnes","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"R82-20250527","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1245\/s10434-021-10022-0","article-title":"Increased local inflammatory response to MOC31PE immunotoxin after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"28","author":"Thorgersen","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"R83-20250527","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1245\/s10434-021-10147-2","article-title":"Intraperitoneal EpCAM-targeted immunotoxin: a first step towards engineering the immune environment in colorectal peritoneal metastases?","volume":"28","author":"Ceelen","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"R84-20250527","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.humpath.2016.02.022","article-title":"Expression of CEA, CA19-9, CA125, and EpCAM in pseudomyxoma peritonei","volume":"54","author":"Nummela","year":"2016","journal-title":"Hum Pathol"},{"key":"R85-20250527","doi-asserted-by":"crossref","first-page":"3000605211022297","DOI":"10.1177\/03000605211022297","article-title":"Prognostic significance of CEA, Ki67 and p53 in pseudomyxoma peritonei of appendiceal origin","volume":"49","author":"Yan","year":"2021","journal-title":"J Int Med Res"},{"key":"R86-20250527","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1245\/s10434-007-9393-9","article-title":"Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"14","author":"Baratti","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"R87-20250527","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/BF02574513","article-title":"Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19-9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy","volume":"9","author":"van Ruth","year":"2002","journal-title":"Ann Surg Oncol"},{"key":"R88-20250527","first-page":"173","article-title":"Carbohydrate antigen 19-9 (CA 19-9) is an independent prognostic indicator in pseudomyxoma peritonei post cytoreductive surgery and perioperative intraperitoneal chemotherapy","volume":"4","author":"Koh","year":"2013","journal-title":"J Gastrointest Oncol"},{"key":"R89-20250527","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1001\/jamaoncol.2018.2805","article-title":"Association of MUC16 mutation with tumor mutation load and outcomes in patients with gastric cancer","volume":"4","author":"Li","year":"2018","journal-title":"JAMA Oncol"},{"key":"R90-20250527","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J Biol Chem"},{"key":"R91-20250527","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1096\/fj.11-195669","article-title":"Mucin 16 is a functional selectin ligand on pancreatic cancer cells","volume":"26","author":"Chen","year":"2012","journal-title":"FASEB J"},{"key":"R92-20250527","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jso.23329","article-title":"Circulating tumor markers: predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei","volume":"108","author":"Kusamura","year":"2013","journal-title":"J Surg Oncol"},{"key":"R93-20250527","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/14728222.2018.1498845","article-title":"MUC16 as a novel target for cancer therapy","volume":"22","author":"Aithal","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"R94-20250527","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ejso.2013.12.021","article-title":"Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: analysis of 519 patients","volume":"40","author":"Taflampas","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"R95-20250527","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/bjs5.50134","article-title":"Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms","volume":"3","author":"van Eden","year":"2019","journal-title":"BJS Open"},{"key":"R96-20250527","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2019.12.008","article-title":"Pathological prognostic factors of pseudomyxoma peritonei: comprehensive clinicopathological analysis of 155 cases","volume":"97","author":"Yan","year":"2020","journal-title":"Hum Pathol"},{"key":"R97-20250527","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1440-1827.2007.02137.x","article-title":"MUC2, MUC5AC and MUC5B in the mucus of a patient with pseudomyxoma peritonei: biochemical and immunohistochemical study","volume":"57","author":"Mall","year":"2007","journal-title":"Pathol Int"},{"key":"R98-20250527","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.humpath.2017.07.014","article-title":"Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer","volume":"71","author":"Wang","year":"2018","journal-title":"Hum Pathol"},{"key":"R99-20250527","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1017\/S0022215119000549","article-title":"Ki-67 index as a predictor of vestibular schwannoma regrowth or recurrence","volume":"133","author":"Prueter","year":"2019","journal-title":"J Laryngol Otol"},{"key":"R100-20250527","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1245\/s10434-021-10372-9","article-title":"A proposal for modification of the PSOGI classification according to the Ki-67 proliferation index in pseudomyxoma peritonei","volume":"29","author":"Arjona-S\u00e1nchez","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"R101-20250527","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3390\/cancers10060154","article-title":"Treating p53 mutant aggregation-associated cancer","volume":"10","author":"Kanapathipillai","year":"2018","journal-title":"Cancers (Basel)"},{"key":"R102-20250527","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ccell.2018.12.012","article-title":"Wild-type p53 promotes cancer metabolic switch by inducing PUMA-dependent suppression of oxidative phosphorylation","volume":"35","author":"Kim","year":"2019","journal-title":"Cancer Cell"},{"key":"R103-20250527","doi-asserted-by":"crossref","first-page":"e99351","DOI":"10.1371\/journal.pone.0099351","article-title":"Impedimetric detection of mutant p53 biomarker-driven metastatic breast cancers under hyposmotic pressure","volume":"9","author":"Shi","year":"2014","journal-title":"PLoS One"},{"key":"R104-20250527","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jmoldx.2018.05.002","article-title":"Analysis of mutation and loss of heterozygosity by whole-exome sequencing yields insights into pseudomyxoma peritonei","volume":"20","author":"Pengelly","year":"2018","journal-title":"J Mol Diagn"},{"key":"R105-20250527","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1053\/j.seminoncol.2007.09.011","article-title":"The RTK\/RAS\/BRAF\/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications","volume":"34","author":"Haluska","year":"2007","journal-title":"Semin Oncol"},{"key":"R106-20250527","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1093\/annonc\/mdw314","article-title":"Toward the molecular dissection of peritoneal pseudomyxoma","volume":"27","author":"Pietrantonio","year":"2016","journal-title":"Ann Oncol"},{"key":"R107-20250527","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12967-016-0877-x","article-title":"GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study","volume":"14","author":"Pietrantonio","year":"2016","journal-title":"J Transl Med"},{"key":"R108-20250527","doi-asserted-by":"crossref","first-page":"e003109","DOI":"10.1136\/jitc-2021-003109","article-title":"Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei","volume":"9","author":"Flatmark","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R109-20250527","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/cam4.542","article-title":"Molecular profiles of high-grade and low-grade pseudomyxoma peritonei","volume":"4","author":"Noguchi","year":"2015","journal-title":"Cancer Med"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T17:08:00Z","timestamp":1748365680000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000911"}},"subtitle":["A Literature Review"],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":107,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000911","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,14]]}}}